We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Risks vs Benefits in Rheumatology: The Current Status of Drug Therapy

JAMA. 1965;194(12):23-27. doi:10.1001/jama.1965.03090250083045.
Text Size: A A A
Published online


Drug therapy for the rheumatoid patient—the selection of an agent and course of treatment—is often a difficult and frustrating task for the physician.

"Nowhere have the problems involved in the selection of a therapeutic agent been more apparent than in the chronic rheumatoid disorders," said Nathan J. Zvaifler, MD. "Lacking a definite etiology, their therapy has frequently been pragmatic or symptomatic."

Added to the unpredictable and varying course of disease is a further complication arising from the nature of the available therapeutic agents: virtually every drug useful in treatment of rheumatoid disease is potentially toxic.

Effects Noted  These toxic effects include gastrointestinal bleeding from salicylates, renal papillary necrosis from phenacetin, blood dyscrasias and peptic ulcers from phenylbutazone, dermatitis and renal complications from gold salts, retinal damage from the antimalarials, purpura, peptic ulcer and osteoporosis from corticosteroids, and gastrointestinal and cerebral complications from the use of indomethacin.Improvement is possible in


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.